This is an automatically translated article.
Diltocatif has the main active ingredient Abacavir (as Abacavir sulfate), which is a reverse transcriptase inhibitor in the treatment of HIV virus. The drug is usually indicated alone or in combination with other antiretroviral agents in the treatment of HIV-1.
1. What is Ditocatif?
Diltocatif has the main active ingredient Abacavir (as Abacavir sulfate), which is a nucleoside reverse transcriptase inhibitor, which is the first class of antiretroviral drugs to be deployed. Diltocatif is prepared in the form of film-coated tablets, the strength of each tablet is 300mg.
What does Diltocatif do? Diltocatif is active against HIV-1 and HIV-2 retroviruses, including HIV-1 strains less susceptible to zidovudine, lamivudine, zalcitabine, didanosin or nevirapine. The drug inhibits the reverse transcriptase enzyme, inhibits the synthesis of the DNA sequence, thereby preventing the virus from replicating. Diltocatif is indicated for use alone or in combination with other antiretroviral agents in the treatment of HIV-1.
2. What is the dosage and usage of Ditocatif?
2.1 How to use Ditocatif Diltocatif is prepared in the form of film-coated tablets, the content of each tablet is 300mg, for oral use. Before taking, patients should carefully read the instructions for use on the drug leaflet and consult a doctor, specialist pharmacist. When swallowed, swallow the tablet whole with a full glass of water. Should be taken at a fixed time of the day to avoid forgetting the dose.
2.2 Dosage of Ditocatif is as follows: Adults: 300mg/time x 2 times/day. Children from 2 months to 16 years old: 8mg/time x 2 times/day, maximum dose 300mg/day. Children under 3 months of age: FDA recommends contraindications for use of Ditocatif. For patients with renal impairment: No dose adjustment is required. Elderly: There is no current information on the effects of Ditocatif in people over 65 years of age.
3. Contraindications of Ditocatif
Absolutely do not use Ditocatif in the following cases:
Patients with a history of allergy or hypersensitivity to Abacavir or to any of its ingredients. Patients with severe, moderate liver failure (child-pugh cirrhosis B, C).
4. Undesirable effects of the drug Ditocatif
Ditocatif can cause some side effects when used as follows:
Systemic: Weight gain, vasculitis, asthenia, hypersensitivity reactions (urticaria, facial edema, laryngeal edema, generalized skin erythema body, rapid or decreased heart rate, shortness of breath,...) Cardiovascular system: Cardiomyopathy. Digestive system: stomatitis, decreased appetite, abdominal pain, dyspepsia, oral mucosal pigmentation changes. Endocrine system and metabolism: hyperglycemia, gynecomastia in men, lipid metabolism disorders, hyperlipidemia. Blood system: aplastic anemia, anemia, lymphadenopathy, splenomegaly, thrombocytopenia. On the liver and pancreas: Increased bilirubin, increased liver enzymes, pancreatitis, hepatitis B outbreak after treatment. Musculoskeletal system: Arthralgia, myalgia, myasthenia gravis, elevated CK enzymes, rhabdomyolysis. Nervous system: somnolence, paresthesia, peripheral neuropathy, generalized convulsions, insomnia, sleep disturbances. Respiratory system: abnormal breathing sounds, wheezing. Skin: Erythema multiforme, Stevens-Johnson syndrome.
5. Precautions when using Ditocatif
When using Ditocatif, the following information should be noted:
Use caution when using Ditocatif in the first 6 weeks, because of the risk of hypersensitivity reactions (4%), sometimes fatal. Detection of a hypersensitivity reaction is often difficult because it is easily confused with a systemic disease. Ditocatif must be discontinued immediately if symptoms of hypersensitivity (urticaria, facial edema, laryngeal edema, generalized skin erythema, tachycardia or decreased, dyspnoea,...) After discontinuation of the drug there is a risk of a particular hypersensitivity reaction even in the absence of symptoms of hypersensitivity. Therefore, the patient must take the medicine regularly, without interruption. Ditocatif should not be used in people with severe liver disease and must be used with extreme caution in people at high risk of liver disease (patients with acute and chronic hepatitis B, C or on combination antiretroviral therapy). . Patients taking Ditocatif need to have liver enzymes, bilirubin, and abdominal ultrasound periodically. Ditocatif should be used with caution in patients with end-stage renal failure. For women who are pregnant. Do not use Ditocatif for pregnant women. Because of the risk of the drug crossing the placenta and causing toxicity to the fetus. Lactation: Not recommended for nursing women or mothers taking Ditocatif who are not breast-feeding. Drivers and Machine Operators: Use Ditocatif with caution.
6. How is it reasonable to store drugs?
Store Ditocatif at room temperature, not exceeding 30°C, away from moisture and mold. Opened Ditocatif vials should not be more than 2 months old. Read the expiry date of the medicine carefully to avoid using the expired medicine. Above is information about Ditocatif medicine for patients to refer to. However, Ditocatif is only used when prescribed by a doctor, patients need to be careful when using it to achieve the best effect and limit unwanted side effects.
